Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
02 Dec 2024
// EXPRESSPHARMA
https://www.expresspharma.in/biocon-biologics-receives-fda-approval-for-biosimilar-yesintek/
28 Nov 2024
// EXPRESSPHARMA
https://www.expresspharma.in/biocon-biologics-supports-diabetes-africa-to-drive-progress-in-embedding-specialist-nurses-in-diabetes-care-in-ethiopia/
19 Nov 2024
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-biologics-looks-to-trim-300-million-debt-in-1-year/articleshow/115451278.cms
05 Nov 2024
// BUSINESS STD
https://www.business-standard.com/companies/interviews/will-launch-3-biosimilars-globally-in-2-3-years-biocon-biologics-ceo-124110501250_1.html
30 Oct 2024
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-biologics-bengaluru-unit-classified-as-voluntary-action-indicated-by-usfda/articleshow/114778927.cms
04 Oct 2024
// EXPRESSPHARMA
https://www.expresspharma.in/biocon-biologics-refinances-1-1-bn-long-term-debt-through-usd-bonds-and-new-syndicated-facility/
Details:
The agreement aims to commercialize its Bmab 1200, a proposed biosimilar to Stelara and a monoclonal antibody medication, in Europe, the United Kingdom (UK), Canada, and Japan.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Brand Name: Bmab 1200
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 29, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocon Settles with Janssen to Commercialise Biosimilar Products in Europe, Canada, Japan
Details : The agreement aims to commercialize its Bmab 1200, a proposed biosimilar to Stelara and a monoclonal antibody medication, in Europe, the United Kingdom (UK), Canada, and Japan.
Brand Name : Bmab 1200
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 29, 2024
Details:
Yesafili (aflibercept) is a PGF & VEGF-A inhibitor, its single-dose vial formulation is approved for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Brand Name: Yesafili
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biocon Biologics gets FDA nod for Yesafili™, enters U.S. ophthalmology market
Details : Yesafili (aflibercept) is a PGF & VEGF-A inhibitor, its single-dose vial formulation is approved for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.
Brand Name : Yesafili
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 21, 2024
Details:
The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACTIBLOK IPR 25
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Eris Pharmaceuticals
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2024
Lead Product(s) : Metoprolol Succinate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Eris Pharmaceuticals
Deal Size : $150.0 million
Deal Type : Collaboration
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln
Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.
Brand Name : ACTIBLOK IPR 25
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 13, 2024
Details:
The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar utilized in patients diagnosed with breast cancer or metastatic stomach cancer.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Brand Name: Ogivri
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 10, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Partnership
Biocon Biologics Partners with Sandoz for Biosimilars
Details : The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar utilized in patients diagnosed with breast cancer or metastatic stomach cancer.
Brand Name : Ogivri
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 10, 2024
Details:
Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Brand Name: Advacan
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Eris Lifesciences
Deal Size: $43.8 million Upfront Cash: Undisclosed
Deal Type: Divestment November 09, 2023
Lead Product(s) : Everolimus
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Eris Lifesciences
Deal Size : $43.8 million
Deal Type : Divestment
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations
Details : Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Brand Name : Advacan
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?